179 related articles for article (PubMed ID: 28604127)
1. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis.
Carrascosa JM; Toro Montecinos M; Ballescá F; Teniente Serra A; Martínez Cáceres E; Ferrándiz C
J Dermatolog Treat; 2018 Mar; 29(2):140-144. PubMed ID: 28604127
[TBL] [Abstract][Full Text] [Related]
2. Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment.
Menting SP; Coussens E; Pouw MF; van den Reek JM; Temmerman L; Boonen H; de Jong EM; Spuls PI; Lambert J
JAMA Dermatol; 2015 Jun; 151(6):616-22. PubMed ID: 25807311
[TBL] [Abstract][Full Text] [Related]
3. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
4. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
[TBL] [Abstract][Full Text] [Related]
5. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
[TBL] [Abstract][Full Text] [Related]
6. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G
BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624
[TBL] [Abstract][Full Text] [Related]
7. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
[TBL] [Abstract][Full Text] [Related]
8. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
[TBL] [Abstract][Full Text] [Related]
10. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
[TBL] [Abstract][Full Text] [Related]
11. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
[TBL] [Abstract][Full Text] [Related]
12. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
Teeple A; Muser E
J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
[No Abstract] [Full Text] [Related]
13. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
Di Lernia V; Bianchi L; Guerriero C; Stingeni L; Gisondi P; Filoni A; Guarneri C; Belloni Fortina A; Lasagni C; Simonetti O; Neri I; Zangrilli A; Moretta G; Hansel K; Casanova DM; Girolomoni G; Cannavò SP; Bonamonte D
Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
[TBL] [Abstract][Full Text] [Related]
15. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
17. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J; Roosenboom B; van de Kerkhof PC; van den Reek JM; Otero ME; Atalay S; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Bijen M; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
20. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.
Mota F; Neves E; Oliveira JC; Selores M; Torres T
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):33-35. PubMed ID: 28632883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
